Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Cost of Revenue (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Cost of Revenue for 6 consecutive years, with $110.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 339.94% year-over-year to $110.1 million, compared with a TTM value of $140.9 million through Dec 2025, up 242.83%, and an annual FY2025 reading of $140.9 million, up 242.83% over the prior year.
  • Cost of Revenue was $110.1 million for Q4 2025 at Treace Medical Concepts, up from -$14.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $110.1 million in Q4 2025 and bottomed at -$65.8 million in Q4 2023.
  • Average Cost of Revenue over 5 years is $13.7 million, with a median of $8.3 million recorded in 2023.
  • The sharpest move saw Cost of Revenue surged 995.01% in 2021, then tumbled 318.64% in 2023.
  • Year by year, Cost of Revenue stood at $5.4 million in 2021, then soared by 460.44% to $30.1 million in 2022, then crashed by 318.64% to -$65.8 million in 2023, then surged by 30.28% to -$45.9 million in 2024, then skyrocketed by 339.94% to $110.1 million in 2025.
  • Business Quant data shows Cost of Revenue for TMCI at $110.1 million in Q4 2025, -$14.9 million in Q3 2025, and $9.6 million in Q2 2025.